Latin American Cooperative Onco-Haematology Group - Peru
* 20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days during the first week, followed by 30 mg three times a week until 12 weeks.
* Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until three different regimens of chemotherapy.
* Follow up for one year after last cycle of alemtuzumab.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Above 18 years old
Eastern Cooperative Oncology Group (ECOG) 0-2
Liver and renal function test less than twice upper label
No active infection
Written informed consent
One to three regimens of previous chemotherapies
You may not be if
Abnormal renal or hepatic function
Mycosis fungoides/Sezary syndrome in transformation